Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5526779 | 0.98 | MAPT (0.51) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| Hydrochloric Acid SCHEMBL17392798 | 0.98 | MAPT (0.47) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| Hydrochloric Acid SCHEMBL5526775 | 0.96 | MAPT (0.50) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL16068213 | 0.95 | MAPT (0.44) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| Hydrochloric Acid SCHEMBL17393194 | 0.93 | MAPT (0.43) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL1189812 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL5523751 | 0.88 | NPSR1 (0.40) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL31252101 | 0.82 | MAPT (0.46) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL13981744 | 0.80 | LMNA (0.39) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL14865353 | 0.80 | NPSR1 (0.35) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115585-A1 | METHOD FOR PRODUCING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | disclosed |
| EP-4353718-A1 | METHOD FOR PRODUCING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-17 | — | — | EP | disclosed |
| CN-117460727-A | Process for producing dihydropyridazine-3, 5-dione derivative | 中外制药株式会社 | 2024-01-26 | — | — | CN | disclosed |
| WO-2022260062-A1 | METHOD FOR PRODUCING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | 中外製薬株式会社 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022260062-A1 | METHOD FOR PRODUCING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | 中外製薬株式会社 | 2022-12-15 | — | — | WO | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9630989-B2 | Dipeptide analogs for treating conditions associated with amyloid fibril formation | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-04-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| CN-101039947-A | Inhibitors of hcv replication | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | CN | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115585-A1 | METHOD FOR PRODUCING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | QDPR, DHPS, DPYD | MAPT 1823/4885NPSR1 3221/4885ALDH1A1 906/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | MAPT 4274/4885NPSR1 3403/4885ALDH1A1 920/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | MAPT 4274/4885NPSR1 3403/4885ALDH1A1 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.